GlaxoSmithKline is eyeing another indication for its Nucala (mepolizumab) biologic drug after a phase 3 trial in inflammation caused by nasal polyps hit its targets, bringing it into competition ...

Simultaneously, the three regulators are also reviewing a second potential indication for depemokimab as an add-on therapy for chronic rhinosinusitis with nasal polyps (CRSwNP). GSK has said ...

IL-5 is present at high levels in nasal polyp tissue. IL-5 inhibitors play a key role in reducing type II inflammation. Year to date, shares of GSK have risen 5.5% against the industry’s decline ...